Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57188 | 1.00 | TUBB1 (0.43) | TUBB1SMN1; SMN2CTSSCNR2KCNA5 | |
| SCHEMBL57412 | 0.93 | TUBB1 (0.45) | TUBB1 | |
| SCHEMBL88423 | 0.93 | TUBB1 (0.45) | TUBB1 | |
| SCHEMBL4380964 | 0.85 | TUBB1 (0.57) | TUBB1 | |
| SCHEMBL4380970 | 0.85 | TUBB1 (0.57) | TUBB1 | |
| SCHEMBL4380969 | 0.85 | TUBB1 (0.57) | TUBB1 | |
| SCHEMBL4373023 | 0.85 | TUBB1 (0.61) | TUBB1SMN1; SMN2CTSSCNR2KCNA5 | |
| SCHEMBL57909 | 0.85 | TUBB1 (0.61) | TUBB1SMN1; SMN2CTSSCNR2KCNA5 | |
| SCHEMBL88733 | 0.85 | TUBB1 (0.61) | TUBB1SMN1; SMN2CTSSCNR2KCNA5 | |
| SCHEMBL88219 | 0.83 | TUBB1 (0.43) | TUBB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2374454-A1 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | Eisai R&D Management Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885SMN1; SMN2 4520/4885CTSS 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.